|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Xiong X, Zheng LW, Ding Y, Chen YF, Cai
YW, Wang LP, Huang L, Liu CC, Shao ZM and Yu KD: Breast cancer:
Pathogenesis and treatments. Signal Transduct Target Ther.
10:492025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan MM, Yalamarty SSK, Rajmalani BA,
Filipczak N and Torchilin VP: Recent strategies to overcome breast
cancer resistance. Crit Rev Oncol Hematol. 197:1043512024.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diener C, Keller A and Meese E: Emerging
concepts of miRNA therapeutics: from cells to clinic. Trends Genet.
38:613–626. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dinami R, Pompili L, Petti E, Porru M,
D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, et
al: MiR-182-3p targets TRF2 and impairs tumor growth of
triple-negative breast cancer. EMBO Mol Med. 15:e160332023.
View Article : Google Scholar :
|
|
6
|
Ho HL, Lin SC, Chiang CW, Lin C, Liu CW,
Yeh YC, Chen MY and Chou TY: miR-193b-3p suppresses lung cancer
cell migration and invasion through PRNP targeting. J Biomed Sci.
32:282025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang T, Hu Y, Yang N, Yu S and Pu X: The
microRNA-34 family and its functional role in lung cancer. Am J
Clin Oncol. 47:448–457. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klicka K, Grzywa TM, Mielniczuk A, Klinke
A and Włodarski PK: The role of miR-200 family in the regulation of
hallmarks of cancer. Front Oncol. 12:9652312022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao Y, Chen W, Wu H, Liu C, Zhang J and
Chen S: Mechanisms and functions of MiR-200 family in
hepatocellular carcinoma. Onco Targets Ther. 13:13479–13490. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu C, Hu W, Li LL, Zhou Q, Zhang F,
Song-Yang YY, Zhu W, Sun CC and Li DJ: Roles of miR-200 family
members in lung cancer: more than tumor suppressors. Future Oncol.
14:2875–2886. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi PW and Ng SW: The Functions of
MicroRNA-200 Family in ovarian cancer: Beyond
epithelial-mesenchymal transition. Int J Mol Sci. 18:12072017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi PS, Zakhary L, Choi WY, Caron S,
Alvarez-Saavedra E, Miska EA, McManus M, Harfe B, Giraldez AJ,
Horvitz HR, et al: Members of the miRNA-200 family regulate
olfactory neurogenesis. Neuron. 57:41–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trümbach D and Prakash N: The conserved
miR-8/miR-200 microRNA family and their role in invertebrate and
vertebrate neurogenesis. Cell Tissue Res. 359:161–177. 2015.
View Article : Google Scholar
|
|
14
|
Lim YY, Wright JA, Attema JL, Gregory PA,
Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y and
Goodall GJ: Epigenetic modulation of the miR-200 family is
associated with transition to a breast cancer stem-cell-like state.
J Cell Sci. 126(Pt 10): 2256–2266. 2013.PubMed/NCBI
|
|
15
|
Vrba L, Garbe JC, Stampfer MR and Futscher
BW: Epigenetic regulation of normal human mammary cell
type-specific miRNAs. Genome Res. 21:2026–2037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Magenta A, Cencioni C, Fasanaro P,
Zaccagnini G, Greco S, Sarra-Ferraris G, Antonini A, Martelli F and
Capogrossi MC: miR-200c is upregulated by oxidative stress and
induces endothelial cell apoptosis and senescence via ZEB1
inhibition. Cell Death Differ. 18:1628–1639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jing J, Xiong S, Li Z, Wu J, Zhou L, Gui
JF and Mei J: A feedback regulatory loop involving p53/miR-200 and
growth hormone endocrine axis controls embryo size of zebrafish.
Sci Rep. 5:159062015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bracken CP, Gregory PA, Kolesnikoff N,
Bert AG, Wang J, Shannon MF and Goodall GJ: A double-negative
feedback loop between ZEB1-SIP1 and the microRNA-200 family
regulates epithelial-mesenchymal transition. Cancer Res.
68:7846–7854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burk U, Schubert J, Wellner U, Schmalhofer
O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression
between ZEB1 and members of the miR-200 family promotes EMT and
invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eades G, Yao Y, Yang M, Zhang Y, Chumsri S
and Zhou Q: miR-200a regulates SIRT1 expression and epithelial to
mesenchymal transition (EMT)-like transformation in mammary
epithelial cells. J Biol Chem. 286:25992–6002. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim HK, Park JD, Choi SH, Shin DJ, Hwang
S, Jung HY and Park KS: Functional link between miR-200a and ELK3
regulates the metastatic nature of breast cancer. Cancers (Basel).
12:12252020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim HY, Ha Thi HT and Hong S: IMP2 and
IMP3 cooperate to promote the metastasis of triple-negative breast
cancer through destabilization of progesterone receptor. Cancer
Lett. 415:30–39. 2018. View Article : Google Scholar
|
|
23
|
Sossey-Alaoui K, Pluskota E, Szpak D,
Schiemann WP and Plow EF: The Kindlin-2 regulation of
epithelial-to-mesenchymal transition in breast cancer metastasis is
mediated through miR-200b. Sci Rep. 8:73602018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peng F, Tang H, Du J, Chen J and Peng C:
Isoliquiritigenin suppresses EMT-Induced metastasis in
triple-negative breast cancer through miR-200c/C-JUN/β-Catenin. Am
J Chin Med. 49:505–523. 2021. View Article : Google Scholar
|
|
25
|
Li RH, Chen M, Liu J, Shao CC, Guo CP, Wei
XL, Li YC, Huang WH and Zhang GJ: Long noncoding RNA ATB promotes
the epithelial-mesenchymal transition by upregulating the
miR-200c/Twist1 axe and predicts poor prognosis in breast cancer.
Cell Death Dis. 9:11712018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li
LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates
breast cancer cell plasticity during EMT and MET plasticity by
differentially sponging miR-200b/c and let-7b. Sci Signal.
10:eaak95572017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren S, Liu J, Feng Y, Li Z, He L, Li L,
Cao X, Wang Z and Zhang Y: Knockdown of circDENND4C inhibits
glycolysis, migration and invasion by up-regulating miR-200b/c in
breast cancer under hypoxia. J Exp Clin Cancer Res. 38:3882019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou D, Gu J, Wang Y, Wu H, Cheng W, Wang
Q, Zheng G and Wang X: Long non-coding RNA NEAT1 transported by
extracellular vesicles contributes to breast cancer development by
sponging microRNA-141-3p and regulating KLF12. Cell Biosci.
11:682021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu M, Wang S, Wang Y, Wu H, Frank JA,
Zhang Z and Luo J: Role of p38γ MAPK in regulation of EMT and
cancer stem cells. Biochim Biophys Acta Mol Basis Dis.
1864:3605–3617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang G, Zhang W, Li B, Stringer-Reasor E,
Chu C, Sun L, Bae S, Chen D, Wei S, Jiao K, et al: MicroRNA-200c
and microRNA-141 are regulated by a FOXP3-KAT2B axis and associated
with tumor metastasis in breast cancer. Breast Cancer Res.
19:732017. View Article : Google Scholar
|
|
31
|
Zeng X, Qu X, Zhao C, Xu L, Hou K, Liu Y,
Zhang N, Feng J, Shi S, Zhang L, et al: FEN1 mediates miR-200a
methylation and promotes breast cancer cell growth via MET and EGFR
signaling. FASEB J. 33:10717–10730. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang X, Tu G, Yang G, Wang X, Kang L, Yang
L, Zeng H, Wan X, Qiao Y, Cui X, et al: Autocrine
TGF-β1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status
to fuel breast cancer cell proliferation. Cancer Lett. 452:79–89.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun S, Ma J, Xie P, Wu Z and Tian X:
Hypoxia-responsive miR-141-3p is involved in the progression of
breast cancer via mediating the HMGB1/HIF-1α signaling pathway. J
Gene Med. 22:e32302020. View Article : Google Scholar
|
|
34
|
Wang JG, Jian WJ, Li Y and Zhang J:
Nobiletin promotes the pyroptosis of breast cancer via regulation
of miR-200b/JAZF1 axis. Kaohsiung J Med Sci. 37:572–582. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye
F and Xie X, Chen J, Tang H and Xie X: miR-200c inhibits breast
cancer proliferation by targeting KRAS. Oncotarget. 6:34968–34978.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Liu Q, Mu Q, Zhou D, Li H, Zhang
B and Yin C: MiR-429 suppresses proliferation and invasion of
breast cancer via inhibiting the Wnt/β-catenin signaling pathway.
Thorac Cancer. 11:3126–3138. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu F, Hu Y, Gao J, Wang J, Xie Y, Sun F,
Wang L, Miyamoto A, Xia O and Zhang C: HIF-1α/Malat1/miR-141 axis
activates autophagy to increase proliferation, migration, and
invasion in triple-negative breast cancer. Curr Cancer Drug
Targets. 23:363–378. 2023. View Article : Google Scholar
|
|
38
|
Sun Y, Yang D, Xi L, Chen Y, Fu L, Sun K,
Yin J, Li X, Liu S, Qin Y, et al: Primed atypical ductal
hyperplasia-associated fibroblasts promote cell growth and polarity
changes of transformed epithelium-like breast cancer MCF-7 cells
via miR-200b/c-IKKβ signaling. Cell Death Dis. 9:1222018.
View Article : Google Scholar
|
|
39
|
Liu B, Du R, Zhou L, Xu J, Chen S, Chen J,
Yang X, Liu DX, Shao ZM, Zhang L, et al: miR-200c/141 regulates
breast cancer stem cell heterogeneity via targeting HIPK1/β-Catenin
axis. Theranostics. 8:5801–5813. 2018. View Article : Google Scholar
|
|
40
|
Saha T, Solomon J, Samson AO and Gil-Henn
H: Invasion and metastasis as a central hallmark of breast cancer.
J Clin Med. 10:34982021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar
|
|
42
|
Brabletz S, Schuhwerk H, Brabletz T and
Stemmler MP: Dynamic EMT: A multi-tool for tumor progression. EMBO
J. 40:e1086472021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ahmad A, Aboukameel A, Kong D, Wang Z,
Sethi S, Chen W, Sarkar FH and Raz A: Phosphoglucose
isomerase/autocrine motility factor mediates epithelial-mesenchymal
transition regulated by miR-200 in breast cancer cells. Cancer Res.
71:3400–3409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lorenzo-Martín LF, Citterio C,
Menacho-Márquez M, Conde J, Larive RM, Rodríguez-Fdez S,
García-Escudero R, Robles-Valero J, Cuadrado M, Fernández-Pisonero
I, et al: Vav proteins maintain epithelial traits in breast cancer
cells using miR-200c-dependent and independent mechanisms.
Oncogene. 38:209–227. 2019. View Article : Google Scholar :
|
|
46
|
Lu Z, Jiao D, Qiao J, Yang S, Yan M, Cui S
and Liu Z: Restin suppressed epithelial-mesenchymal transition and
tumor metastasis in breast cancer cells through upregulating
mir-200a/b expression via association with p73. Mol Cancer.
14:1022015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roy SS, Gonugunta VK, Bandyopadhyay A, Rao
MK, Goodall GJ, Sun LZ, Tekmal RR and Vadlamudi RK: Significance of
PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of
breast cancer. Oncogene. 33:3707–3716. 2014. View Article : Google Scholar
|
|
48
|
Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing
C, Gao K, Liu ZH and Yu SJ: miR-429 inhibits migration and invasion
of breast cancer cells in vitro. Int J Oncol. 46:531–538. 2015.
View Article : Google Scholar
|
|
49
|
Zhang Y, Li J, Jia S, Wang Y, Kang Y and
Zhang W: Down-regulation of lncRNA-ATB inhibits
epithelial-mesenchymal transition of breast cancer cells by
increasing miR-141-3p expression. Biochem Cell Biol. 97:193–200.
2019. View Article : Google Scholar
|
|
50
|
Zou Q, Zhou E, Xu F, Zhang D, Yi W and Yao
J: A TP73-AS1/miR-200a/ZEB1 regulating loop promotes breast cancer
cell invasion and migration. J Cell Biochem. 119:2189–2199. 2018.
View Article : Google Scholar
|
|
51
|
Damiano V, Brisotto G, Borgna S, di
Gennaro A, Armellin M, Perin T, Guardascione M, Maestro R and
Santarosa M: Epigenetic silencing of miR-200c in breast cancer is
associated with aggressiveness and is modulated by ZEB1. Genes
Chromosomes Cancer. 56:147–158. 2017. View Article : Google Scholar
|
|
52
|
Sundararajan V, Gengenbacher N, Stemmler
MP, Kleemann JA, Brabletz T and Brabletz S: The ZEB1/miR-200c
feedback loop regulates invasion via actin interacting proteins
MYLK and TKS5. Oncotarget. 6:27083–27096. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Teng Y, Mei Y, Hawthorn L and Cowell JK:
WASF3 regulates miR-200 inactivation by ZEB1 through suppression of
KISS1 leading to increased invasiveness in breast cancer cells.
Oncogene. 33:203–211. 2014. View Article : Google Scholar :
|
|
54
|
Bendoraite A, Knouf EC, Garg KS, Parkin
RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY,
Drescher CW, et al: Regulation of miR-200 family microRNAs and ZEB
transcription factors in ovarian cancer: Evidence supporting a
mesothelial-to-epithelial transition. Gynecol Oncol. 116:117–125.
2010. View Article : Google Scholar
|
|
55
|
Wang Y, Wu Z and Hu L: The regulatory
effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in
the epithelial-mesenchymal transition(EMT) for colorectal
cancer(CRC). Eur J Pharmacol. 834:45–53. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pruitt K, Zinn RL, Ohm JE, McGarvey KM,
Kang SH, Watkins DN, Herman JG and Baylin SB: Inhibition of SIRT1
reactivates silenced cancer genes without loss of promoter DNA
hypermethylation. PLoS Genet. 2:e402006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cho HJ, Oh N, Park JH, Kim KS, Kim HK, Lee
E, Hwang S, Kim SJ and Park KS: ZEB1 Collaborates with ELK3 to
Repress E-Cadherin expression in triple-negative breast cancer
cells. Mol Cancer Res. 17:2257–2266. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tsai JH, Donaher JL, Murphy DA, Chau S and
Yang J: Spatiotemporal regulation of epithelial-mesenchymal
transition is essential for squamous cell carcinoma metastasis.
Cancer Cell. 22:725–736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gilmore AP: Anoikis. Cell Death Differ.
12(Suppl 2): S1473–S1477. 2005. View Article : Google Scholar
|
|
60
|
Yuan M, Tomlinson V, Lara R, Holliday D,
Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P,
Danovi SA, et al: Yes-associated protein (YAP) functions as a tumor
suppressor in breast. Cell Death Differ. 15:1752–1759. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di
GH, Wu J, Shen ZZ, Song HY and Shao ZM: MicroRNA-200a promotes
anoikis resistance and metastasis by targeting YAP1 in human breast
cancer. Clin Cancer Res. 19:1389–1399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Howe EN, Cochrane DR and Richer JK:
Targets of miR-200c mediate suppression of cell motility and
anoikis resistance. Breast Cancer Res. 13:R452011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kozak J, Wdowiak P, Maciejewski R and
Torres A: Interactions between microRNA-200 family and Sestrin
proteins in endometrial cancer cell lines and their significance to
anoikis. Mol Cell Biochem. 459:21–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Miao H, Li DQ, Mukherjee A, Guo H, Petty
A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, et al: EphA2
mediates ligand-dependent inhibition and ligand-independent
promotion of cell migration and invasion via a reciprocal
regulatory loop with Akt. Cancer Cell. 16:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tsouko E, Wang J, Frigo DE, Aydoğdu E and
Williams C: miR-200a inhibits migration of triple-negative breast
cancer cells through direct repression of the EPHA2 oncogene.
Carcinogenesis. 36:1051–1060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ming J, Zhou Y, Du J, Fan S, Pan B, Wang
Y, Fan L and Jiang J: Identification of miR-200a as a novel
suppressor of connexin 43 in breast cancer cells. Biosci Rep.
35:e002512015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Clucas J and Valderrama F: ERM proteins in
cancer progression. J Cell Sci. 127(Pt 2): 267–275. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hong H, Yu H, Yuan J, Guo C, Cao H, Li W
and Xiao C: MicroRNA-200b impacts breast cancer cell migration and
invasion by regulating ezrin-radixin-moesin. Med Sci Monit.
22:1946–1952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li X, Roslan S, Johnstone CN, Wright JA,
Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ,
et al: MiR-200 can repress breast cancer metastasis through
ZEB1-independent but moesin-dependent pathways. Oncogene.
33:4077–4088. 2014. View Article : Google Scholar
|
|
70
|
Yuan J, Xiao C, Lu H, Yu H, Hong H, Guo C
and Wu Z: miR-200b regulates breast cancer cell proliferation and
invasion by targeting radixin. Exp Ther Med. 19:2741–2750.
2020.PubMed/NCBI
|
|
71
|
Zhang X, Yu X, Zhao Z, Yuan Z, Ma P, Ye Z,
Guo L, Xu S, Xu L, Liu T, et al: MicroRNA-429 inhibits bone
metastasis in breast cancer by regulating CrkL and MMP-9. Bone.
130:1151392020. View Article : Google Scholar
|
|
72
|
Choi SK, Kim HS, Jin T, Hwang EH, Jung M
and Moon WK: Overexpression of the miR-141/200c cluster promotes
the migratory and invasive ability of triple-negative breast cancer
cells through the activation of the FAK and PI3K/AKT signaling
pathways by secreting VEGF-A. BMC Cancer. 16:5702016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Jin T, Suk Kim H, Ki Choi S, Hye Hwang E,
Woo J, Suk Ryu H, Kim K, Moon A and Kyung Moon W: microRNA-200c/141
upregulates SerpinB2 to promote breast cancer cell metastasis and
reduce patient survival. Oncotarget. 8:32769–32782. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Humphries B, Wang Z, Oom AL, Fisher T, Tan
D, Cui Y, Jiang Y and Yang C: MicroRNA-200b targets protein kinase
Cα and suppresses triple-negative breast cancer metastasis.
Carcinogenesis. 35:2254–2263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Humphries B, Wang Z, Li Y, Jhan JR, Jiang
Y and Yang C: ARHGAP18 downregulation by miR-200b suppresses
metastasis of triple-negative breast cancer by enhancing activation
of RhoA. Cancer Res. 77:4051–4064. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sigloch FC, Burk UC, Biniossek ML,
Brabletz T and Schilling O: miR-200c dampens cancer cell migration
via regulation of protein kinase A subunits. Oncotarget.
6:23874–23889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li P, Xu T, Zhou X, Liao L, Pang G, Luo W,
Han L, Zhang J, Luo X, Xie X and Zhu K: Downregulation of miRNA-141
in breast cancer cells is associated with cell migration and
invasion: involvement of ANP32E targeting. Cancer Med. 6:662–672.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zheng Q, Cui X, Zhang D, Yang Y, Yan X,
Liu M, Niang B, Aziz F, Liu S, Yan Q and Liu J: miR-200b inhibits
proliferation and metastasis of breast cancer by targeting
fucosyltransferase IV and α1,3-fucosylated glycans. Oncogenesis.
6:e3582017. View Article : Google Scholar
|
|
79
|
Liu Y, Tang J, Qiu X, Teng LA, Sriwastva
MK, Han X, Li Z, Liu M, Liu S, Da D, et al: Rab1A-mediated exosomal
sorting of miR-200c enhances breast cancer lung metastasis. Breast
Cancer (Dove Med Press). 15:403–419. 2023.PubMed/NCBI
|
|
80
|
Yao J, Zhou E, Wang Y, Xu F, Zhang D and
Zhong D: microRNA-200a inhibits cell proliferation by targeting
mitochondrial transcription factor A in breast cancer. DNA Cell
Biol. 33:291–300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu Y, Kao HI and Bambara RA: Flap
endonuclease 1: A central component of DNA metabolism. Annu Rev
Biochem. 73:589–615. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zheng L, Dai H, Zhou M, Li M, Singh P, Qiu
J, Tsark W, Huang Q, Kernstine K, Zhang X, et al: Fen1 mutations
result in autoimmunity, chronic inflammation and cancers. Nat Med.
13:812–819. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
83
|
Peng G, Yan J, Shi P and Li H: LINC01140
hinders the development of breast cancer through targeting
miR-200b-3p to downregulate DMD. Cell Transplant.
32:96368972312112022023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Jones R, Watson K, Bruce A, Nersesian S,
Kitz J and Moorehead R: Re-expression of miR-200c suppresses
proliferation, colony formation and in vivo tumor growth of murine
claudin-low mammary tumor cells. Oncotarget. 8:23727–23749. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang C, Ju H, Shen C and Tong Z: miR-429
mediates δ-tocotrienol-induced apoptosis in triple-negative breast
cancer cells by targeting XIAP. Int J Clin Exp Med. 8:15648–15656.
2015.
|
|
86
|
Bi M, Zheng L, Chen L, He J, Yuan C, Ma P,
Zhao Y, Hu F, Tang W and Sheng M: ln RNA LINC01234 promotes
triple-negative breast cancer progression through regulating the
miR-429/SYNJ1 axis. Am J Transl Res. 13:11399–11412.
2021.PubMed/NCBI
|
|
87
|
Li Y, Meng X, Luo Y, Luo S, Li J, Zeng J,
Huang X and Wang J: The oncogenic miR-429 promotes triple-negative
breast cancer progression by degrading DLC1. Aging (Albany NY).
15:9809–9821. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Dong S, Ma M, Li M, Guo Y, Zuo X, Gu X,
Zhang M and Shi Y: LncRNA MEG3 regulates breast cancer
proliferation and apoptosis through miR-141-3p/RBMS3 axis.
Genomics. 113:1689–1704. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wang X, Ji C, Hu J, Deng X, Zheng W, Yu Y,
Hua K, Zhou X and Fang L: Hsa_circ_0005273 facilitates breast
cancer tumorigenesis by regulating YAP1-hippo signaling pathway. J
Exp Clin Cancer Res. 40:292021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yao Y, Hu J, Shen Z, Yao R, Liu S, Li Y,
Cong H, Wang X, Qiu W and Yue L: MiR-200b expression in breast
cancer: A prognostic marker and act on cell proliferation and
apoptosis by targeting Sp1. J Cell Mol Med. 19:760–769. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Wang W, Li Y, Zhu JY, Fang D, Ding HF,
Dong Z, Jing Q, Su SB and Huang S: Triple negative breast cancer
development can be selectively suppressed by sustaining an elevated
level of cellular cyclic AMP through simultaneously blocking its
efflux and decomposition. Oncotarget. 7:87232–87245. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhang DD, Li Y, Xu Y, Kim J and Huang S:
Phosphodiesterase 7B/microRNA-200c relationship regulates
triple-negative breast cancer cell growth. Oncogene. 38:1106–1120.
2019. View Article : Google Scholar
|
|
93
|
Li D, Wang H, Song H, Xu H, Zhao B, Wu C,
Hu J, Wu T, Xie D, Zhao J, et al: The microRNAs miR-200b-3p and
miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and
motility of breast cancer cells. Oncotarget. 8:85276–85289. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bahrami A, Hassanian SM, Khazaei M,
Hasanzadeh M, Shahidsales S, Maftouh M, Ferns GA and Avan A: The
therapeutic potential of targeting tumor microenvironment in breast
cancer: rational strategies and recent progress. J Cell Biochem.
119:111–122. 2018. View Article : Google Scholar
|
|
95
|
Lin Z, Roche ME, Díaz-Barros V,
Domingo-Vidal M, Whitaker-Menezes D, Tuluc M, Uppal G, Caro J,
Curry JM and Martinez-Outschoorn U: MiR-200c reprograms fibroblasts
to recapitulate the phenotype of CAFs in breast cancer progression.
Cell Stress. 8:1–20. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Meng Z, Zhang R, Wang Y, Zhu G, Jin T, Li
C and Zhang S: miR-200c/PAI-2 promotes the progression of triple
negative breast cancer via M1/M2 polarization induction of
macrophage. Int Immunopharmacol. 81:1060282020. View Article : Google Scholar
|
|
97
|
Raue R, Frank AC, Fuhrmann DC, de la
Cruz-Ojeda P, Rösser S, Bauer R, Cardamone G, Weigert A, Syed SN,
Schmid T and Brüne B: MicroRNA-200c attenuates the
tumor-infiltrating capacity of macrophages. Biology (Basel).
11:3492022.PubMed/NCBI
|
|
98
|
Yang F, Xu J, Tang L and Guan X: Breast
cancer stem cell: the roles and therapeutic implications. Cell Mol
Life Sci. 74:951–966. 2017. View Article : Google Scholar
|
|
99
|
Hsu TW, Chen HA, Liao PH, Su YH, Chiu CF,
Huang CY, Lin YJ, Hung CC, Yeh MH, Sung SY and Su CM:
Dicer-mediated miR-200b expression contributes to cell
migratory/invasive abilities and cancer stem cells properties of
breast cancer cells. Aging (Albany NY). 14:6520–6536. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Iliopoulos D, Lindahl-Allen M, Polytarchou
C, Hirsch HA, Tsichlis PN and Struhl K: Loss of miR-200 inhibition
of Suz12 leads to polycomb-mediated repression required for the
formation and maintenance of cancer stem cells. Mol Cell.
39:761–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Tang H, Song C, Ye F, Gao G, Ou X, Zhang L
and Xie X and Xie X: miR-200c suppresses stemness and increases
cellular sensitivity to trastuzumab in HER2+ breast cancer. J Cell
Mol Med. 23:8114–8127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wu D, Ji N and Zhang L and Zhang L:
Differential expression of miR-200c in breast cancer stem cells.
Int J Clin Exp Pathol. 10:10085–10091. 2017.PubMed/NCBI
|
|
103
|
Liu S, Cong Y, Wang D, Deng L, Liu Y,
Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, et al:
Breast cancer stem cells transition between epithelial and
mesenchymal states reflective of their normal counterparts. Stem
Cell Reports. 2:78–91. 2013. View Article : Google Scholar
|
|
104
|
Lee Y, Ni J, Beretov J, Wasinger VC,
Graham P and Li Y: Recent advances of small extracellular vesicle
biomarkers in breast cancer diagnosis and prognosis. Mol Cancer.
22:332023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Yang T, Li W, Huang T and Zhou J: Genetic
testing enhances the precision diagnosis and treatment of breast
cancer. Int J Mol Sci. 24:166072023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Cardinali B, Tasso R, Piccioli P, Ciferri
MC, Quarto R and Del Mastro L: Circulating miRNAs in breast cancer
diagnosis and prognosis. Cancers (Basel). 14:23172022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Xu F, He H, Huang W, Lin Y, Luo S, Du Q
and Duan R: Decreased expression of MicroRNA-200 family in human
breast cancer is associated with lymph node metastasis. Clin Transl
Oncol. 18:283–288. 2016. View Article : Google Scholar
|
|
108
|
Fahim SA, Abdullah MS, Espinoza-Sánchez
NA, Hassan H, Ibrahim AM, Ahmed SH, Shakir G, Badawy MA, Zakhary
NI, Greve B, et al: Inflammatory breast carcinoma: Elevated
microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and
miR-203a-3p expression as potential biomarkers with diagnostic
value. Biomolecules. 10:10592020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Qiao P, Du H, Guo X, Yu M, Zhang C and Shi
Y: Serum exosomal miR-200c is a potential diagnostic biomarker for
breast cancer. Biomarkers. 29:419–426. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Khalil M, Desouky EM, Khaliefa AK, Hozyen
WG, Mohamed SS and Hasona NA: Insights into the crosstalk between
miR-200a/lncRNA H-19 and IL-6/SIRT-1 axis in breast cancer. J
Interferon Cytokine Res. 44:191–197. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Papadaki C, Stoupis G, Tsalikis L,
Monastirioti A, Papadaki M, Maliotis N, Stratigos M, Mastrostamatis
G, Mavroudis D and Agelaki S: Circulating miRNAs as a marker of
metastatic disease and prognostic factor in metastatic breast
cancer. Oncotarget. 10:966–981. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Braicu C, Raduly L, Morar-Bolba G,
Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A,
Irimie A, et al: Aberrant miRNAs expressed in HER-2 negative breast
cancers patient. J Exp Clin Cancer Res. 37:2572018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Ye F, Tang H, Liu Q and Xie X, Wu M, Liu
X, Chen B and Xie X: miR-200b as a prognostic factor in breast
cancer targets multiple members of RAB family. J Transl Med.
12:172014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Amorim M, Lobo J, Fontes-Sousa M,
Estevão-Pereira H, Salta S, Lopes P, Coimbra N, Antunes L, Palma de
Sousa S, Henrique R and Jerónimo C: Predictive and prognostic value
of selected MicroRNAs in luminal breast cancer. Front Genet.
10:8152019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Fischer C, Deutsch TM, Feisst M, Rippinger
N, Riedel F, Hartkopf AD, Brucker SY, Domschke C, Fremd C, Michel
L, et al: Circulating miR-200 family as predictive markers during
systemic therapy of metastatic breast cancer. Arch Gynecol Obstet.
306:875–885. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Fischer C, Turchinovich A, Feisst M,
Riedel F, Haßdenteufel K, Scharli P, Hartkopf AD, Brucker SY,
Michel L, Burwinkel B, et al: Circulating miR-200 family and CTCs
in metastatic breast cancer before, during, and after a new line of
systemic treatment. Int J Mol Sci. 23:95352022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Madhavan D, Peng C, Wallwiener M, Zucknick
M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, et
al: Circulating miRNAs with prognostic value in metastatic breast
cancer and for early detection of metastasis. Carcinogenesis.
37:461–470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Shao B, Wang X, Zhang L, Li D, Liu X, Song
G, Cao H, Zhu J and Li H: Plasma microRNAs predict chemoresistance
in patients with metastatic breast cancer. Technol Cancer Res
Treat. 18:15330338198287092019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Navarro-Manzano E, Luengo-Gil G,
González-Conejero R, García-Garre E, García-Martínez E,
García-Torralba E, Chaves-Benito A, Vicente V and Ayala de la Peña
F: Prognostic and predictive effects of tumor and plasma
miR-200c-3p in locally advanced and metastatic breast cancer.
Cancers (Basel). 14:23902022. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Hamam R, Hamam D, Alsaleh KA, Kassem M,
Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating
microRNAs in breast cancer: novel diagnostic and prognostic
biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Moldovan L, Batte KE, Trgovcich J, Wisler
J, Marsh CB and Piper M: Methodological challenges in utilizing
miRNAs as circulating biomarkers. J Cell Mol Med. 18:371–390. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Abu Samaan TM, Samec M, Liskova A, Kubatka
P and Büsselberg D: Paclitaxel's mechanistic and clinical effects
on breast cancer. Biomolecules. 9:7892019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and
Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing
TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Yang C, Liu L, Gao C, Zhang G, Zhang Y,
Zhang S, Li J and Liu Y: Circ_0,007,331 Promotes the PTX Resistance
and Progression of Breast Cancer via miR-200b-3p/ANLN. J Surg Res.
279:619–632. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Li J, Kang J, Liu W, Liu J, Pan G, Mao A,
Zhang Q, Lu J, Ding J and Li H: Docetaxel-resistant triple-negative
breast cancer cell-derived exosomal lncRNA LINC00667 reduces the
chemo-sensitivity of breast cancer cells to docetaxel
<em>via</em> targeting miR-200b-3p/Bcl-2 axis. Eur J
Histochem. 66:35292022. View Article : Google Scholar
|
|
126
|
Chen J, Tian W, He H, Chen F, Huang J,
Wang X and Chen Z: Downregulation of miR-200c-3p contributes to the
resistance of breast cancer cells to paclitaxel by targeting SOX2.
Oncol Rep. 40:3821–3829. 2018.PubMed/NCBI
|
|
127
|
Duan WL, Wang XJ, Guo A, Gu LH, Sheng ZM,
Luo H, Yang LX, Wang WH and Zhang BG: miR-141-3p promotes
paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2
signaling pathway in breast cancer. J Cancer. 15:5622–5635. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Tao S, Ji Y, Li R, Xiao Y, Wu H, Ye R, Shi
J, Geng C, Tang G, Ran R, et al: Layered double hydroxide
LDH-Loaded miR-141-3p Targets RAB10 suppressing cellular autophagy
to reverse paclitaxel resistance in breast cancer. ACS Omega.
10:5886–5899. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hu K, Liu X, Li Y, Li Q, Xu Y, Zeng W,
Zhong G and Yu C: Exosomes mediated transfer of Circ_UBE2D2
enhances the resistance of breast cancer to tamoxifen by binding to
MiR-200a-3p. Med Sci Monit. 26:e9222532020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Gao Y, Zhang W, Liu C and Li G: miR-200
affects tamoxifen resistance in breast cancer cells through
regulation of MYB. Sci Rep. 9:188442019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Safaei S, Amini M, Najjary S, Mokhtarzadeh
A, Bolandi N, Saeedi H, Alizadeh N, Javadrashid D and Baradaran B:
miR-200c increases the sensitivity of breast cancer cells to
Doxorubicin through downregulating MDR1 gene. Exp Mol Pathol.
125:1047532022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Zhang M, Wang F, Xiang Z, Huang T and Zhou
WB: LncRNA XIST promotes chemoresistance of breast cancer cells to
doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin Exp
Pharmacol Physiol. 47:1464–1472. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Alam F, Mezhal F, El Hasasna H, Nair VA,
Aravind SR, Saber Ayad M, El-Serafi A and bdel-Rahman WM: The role
of p53-microRNA 200-Moesin axis in invasion and drug resistance of
breast cancer cells. Tumour Biol. 39:10104283177146342017.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Song W, Wu S, Wu Q, Zhou L, Yu L, Zhu B
and Gong X: The microRNA-141-3p/CDK8 pathway regulates the
chemosensitivity of breast cancer cells to trastuzumab. J Cell
Biochem. 120:14095–14106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Maierthaler M, Benner A, Hoffmeister M,
Surowy H, Jansen L, Knebel P, Chang-Claude J, Brenner H and
Burwinkel B: Plasma miR-122 and miR-200 family are prognostic
markers in colorectal cancer. Int J Cancer. 140:176–187. 2017.
View Article : Google Scholar
|
|
136
|
Prinz C, Frese R, Grams M and Fehring L:
Emerging role of microRNA dysregulation in diagnosis and prognosis
of extrahepatic cholangiocarcinoma. Genes (Basel). 13:14792022.
View Article : Google Scholar : PubMed/NCBI
|
